2018
DOI: 10.1016/j.jval.2018.04.1826
|View full text |Cite
|
Sign up to set email alerts
|

Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
54
1
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 48 publications
(60 citation statements)
references
References 16 publications
4
54
1
1
Order By: Relevance
“…Medicine prices are cited among the causes of shortages worldwide (Jia and Zhao, 2017;Bochenek et al, 2018;Heiskenen et al, 2017;De Weerdt et al, 2015b;Dave et al, 2018). Indeed, especially for low-price medicinal products, the market competition may affect the economic sustainability of the MAHs significantly, decreasing their manufacturing capacity and resilience to demand fluctuation.…”
Section: Strategies To Improve Economic Sustainabilitymentioning
confidence: 99%
See 1 more Smart Citation
“…Medicine prices are cited among the causes of shortages worldwide (Jia and Zhao, 2017;Bochenek et al, 2018;Heiskenen et al, 2017;De Weerdt et al, 2015b;Dave et al, 2018). Indeed, especially for low-price medicinal products, the market competition may affect the economic sustainability of the MAHs significantly, decreasing their manufacturing capacity and resilience to demand fluctuation.…”
Section: Strategies To Improve Economic Sustainabilitymentioning
confidence: 99%
“…Moreover, excessive fragmentation of the National regulatory frameworks may be itself a cause of drug shortage. The relationship between the price policies and availability of medicinal products is known (Dave et al, 2018;De Weerdt et al, 2015b). Considering the different reimbursement policies of Member States (WHO, 2018), the price of the same medicinal product may vary significantly around Europe.…”
Section: Introductionmentioning
confidence: 99%
“…When drugs are in shortage, their prices may increase, placing financial burdens on patients, providers, and payers (Dave et al 2018;Hernandez et al 2019). 10 Additionally, drugs used as substitutes may be more expensive or may not optimize clinical therapy when compared to the original drug of choice.…”
Section: Financial Burdensmentioning
confidence: 99%
“…However, the authors noted that their findings might not be generalizable to drugs that became generics after 2008 or those commonly used in an inpatient setting. (Dave et al 2018) Yurukoglu et al examined whether reduced reimbursement under Medicare Part B contributed to shortages of sterile injectable drugs (Yurukoglu et al 2017). They found that, after the policy change under the Medicare Modernization Act, shortages rose more for drugs with (1) higher shares of patients insured by Medicare, (2) greater decreases in provider reimbursement, and (3) greater decreases in manufacturers' prices.…”
Section: Published Researchmentioning
confidence: 99%
“…This observation raises questions about generic drug pricing, for which some argue that Canada pays too much, 9 while others believe we pay too little and thereby exacerbate shortages through Canada's strict rules against raising prices. 10 Whatever authors of clinical practice guidelines wished to accomplish, it seems doubtful that they wanted β-blockers to disappear. Are physicians inadvertently complicit in the production of drug shortages?…”
Section: Guideline Impactmentioning
confidence: 99%